Advanced Cardiac Therapeutics Completes $5 Million Financing

Laguna Beach, California (ots/PRNewswire) - Advanced Cardiac
Therapeutics, Inc. ("ACT"), a developer of advanced irrigated cardiac
ablation systems, announced today that it has completed a $5 million
'Series B' equity financing. The financing was led by NBGI Ventures,
a venture capital firm specialized in medical technology investments,
and is expected to fund commercialisation in Europe.

ACT was founded in 2007 to develop a novel irrigated
radiofrequency cardiac ablation catheter with a diagnostic
application of established microwave radiometry technology in
association with the founder of the technology, Dr Kenneth Carr, and
an experienced catheter development partner, Contract Medical
International, based in Dresden, Germany.

Cardiac catheter ablation procedures are used to treat a variety
of cardiac arrhythmias including Atrial Fibrillation (AF), which is
estimated to affect over five million people in the USA and Europe.
The procedures involve advancing a catheter into the heart and
selectively ablating certain areas of tissue in order to prevent the
spread of electrical signals that give rise to the arrhythmia. Most
catheter ablation procedures are now conducted with irrigated
catheters, in which saline is pumped through the tip during the
application of energy, in order to prevent the tip from overheating
and increasing risk of blood clotting events. However, as the tip is
cooled, it is not possible to estimate the effect of the energy on
the tissue by measuring the temperature at the surface of the tissue.
ACT's technology will enable for the first time measurement of tissue
temperature with an irrigated catheter. This will permit
Electro-Physiologists greater control in their lesion creation and
has the potential to improve patient outcomes.

"Unlike any other catheter today, ACT's technology allows the
Electro-Physiologist to optimize irrigated catheter generated lesions
by knowing the real time ablation temperature inside the cardiac
tissue", Peter van der Sluis, ACT's CEO, commented. "The completion
of our B round funding allows us to fully prepare for the commercial
launch of ACT's technology in 2010."

Gerard Harper of NBGI Ventures added: "We are delighted to
support this exciting opportunity within the rapidly-growing cardiac
catheter ablation market. ACT's system has potential to bring a
step-change in lesion control during these procedures and improve
outcomes for patients."

About Advanced Cardiac Therapeutics

Headquartered in Laguna Beach, California, USA, ACT specializes
in advanced irrigated cardiac catheter ablation systems with
proprietary temperature-sensing technology based on microwave
radiometry.

About NBGI Ventures (http://www.nbgiventures.com)

NBGI Ventures, established in 2001, manages funds with over
EUR100 million in total commitments and focuses on leading
investments in innovative medical technology companies. NBGI Ventures
is based in London and considers investments across Europe and the
US. Companies it has supported to date include Advanced Cardiac
Therapeutics (USA), Biospace Med (France), BoneSupport (Sweden),
Estech (USA), Forth Photonics (UK), Quanta Fluid Solutions (UK),
Reverse Medical (USA), SuperSonic Imagine (France), 2010 Perfect
Vision (Germany) and Upfront Chromatography (Denmark). NBGI Ventures
is a division of NBGI Private Equity Limited, which is authorised and
regulated by the Financial Services Authority.

For more information contact:
Advanced Cardiac Therapeutics
Peter van der Sluis, CEO
T: +1-949-500-0192
E: pvandersluis@actmed.net
Media enquiries:
Hogarth
Julian Walker / Sarah MacLeod
T: +44(0)20-7357-9477

ots Originaltext: Advanced Cardiac Therapeutics
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: For more information contact: Advanced Cardiac
Therapeutics,Peter van der Sluis, CEO, T: +1-949-500-0192, E:
pvandersluis@actmed.net;Media enquiries: Hogarth, Julian Walker /
Sarah MacLeod, T:+44(0)20-7357-9477